BIA response to proposed review of the statutory scheme for branded medicines pricing

The BIA has responded to the Department for Health and Social Care (DHSC) proposed review of the statutory scheme for branded medicines pricing. For further details about the consultation, please visit the consultation page on the DHSC website.

The BIA is supportive of a statutory and voluntary scheme that enhances patient access to cost-effective medicines and supports the growth of the UK life science sector. However, we are concerned that the proposals risk impacting the attractiveness of the UK as a destination to invest, research and launch new medicines, with significant implications for patients, the economy and the UK's life science ecosystem.

We are calling for a shift in government’s approach towards medicines spending, recognising them as a key investment that benefits the health and wealth of the nation. We recommend that a more sustainable and pro-innovation approach is needed, which enables medicines to receive the same proportional increase in funding as the rest of the NHS and encourages companies to prioritise the UK market.